98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics

98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics

Al leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. Al joined Sage as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Earlier, as Senior Director and Head of the Neuroscience Discovery Chemistry Department of Wyeth Research, Al led a group that successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. He has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 50 patents and patent applications. Al holds a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Maalis 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Helmi 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Helmi 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Tammi 21min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
hippokrateen-vastaanotolla
rss-hereilla
tiedekulma-podcast
docemilia
filocast-filosofian-perusteet
rss-tiedetta-vai-tarinaa
rss-totuuden-liepeilla
utelias-mieli
ihanat-ipanat
sotataidon-ytimessa
radio-antro
rss-bios-podcast
rss-vaasan-yliopiston-podcastit
rss-poliisin-mieli
rss-ammamafia
rss-laakaripodi
rss-kasvikutsut